Publications on or relating to CV301 (PANVAC or CEA-MUC-1-TRICOM).
Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cellsCancer Immunol Immunother. 2016; 65: 537–549.
Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in MicePLoS One. 2016 Feb 24;11(2):e0150084. https://doi.org/10.1371/journal.pone.0150084
Magnitude and quality of tumor-infiltrating T cell response upon poxvirus-based active immunotherapy alone and in combination with CTLA-4 immune checkpoint inhibition.J Clin Oncol. 2014;32:5s suppl: Abstract 3013.
Anti-tumor efficacy of poxvirus-based active immunotherapy alone and in combination with reduced doses of multiple immune checkpoint inhibitors.J Clin Oncol. 2014;32:5s suppl: Abstract 3058.
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.Clin Cancer Res. 2011;17:7164-7173.
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.Clin Cancer Res. 2008;14:3060-3069.
PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma.Expert Opin Biol Ther. 2007;7:543-554.
A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer.Clin Breast Cancer. 2006;7:176-179.